- Home
- AVK vs CRMD Comparison
AVK vs CRMD Comparison
Compare AVK & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVK | CRMD |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.9M | 605.9M |
| IPO Year | 2003 | 2009 |
Fundamental Metrics
Financial Performance| Metric | AVK | CRMD |
|---|---|---|
| Price | $12.51 | $7.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 154.6K | ★ 1.7M |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.03 |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | ★ $43,472,170.00 |
| Revenue This Year | N/A | $627.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.59 |
| Revenue Growth | N/A | ★ 66363.08 |
| 52 Week Low | $9.75 | $5.60 |
| 52 Week High | $13.10 | $17.43 |
Technical Indicators
Market Signals| Indicator | AVK | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 35.24 |
| Support Level | $12.00 | $6.55 |
| Resistance Level | $12.87 | $8.53 |
| Average True Range (ATR) | 0.14 | 0.30 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 8.70 | 7.19 |
Price Performance
Historical ComparisonAbout AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.